Surenano Science Ltd · CSE:SURE
Surenano Science — Investor Presentation (March 2026)
21 slides from Surenano Science's investor presentation, March 2026
Slide 1: Next Generation GLP Peptide in FDA Approval
NEXT GENERATION GLP PEPTIDE IN FDA APPROVAL IN PARTNERSHIP WITH SYRACUSE UNIVERSITY INVESTOR PRESENTATION Q12026 CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 2: Glucapharm advancing Syracuse University's GEP-44
GLUCAPHARM INC., 100%-OWNED SUBSIDIARY OF SURENANO SCIENCE LTD. (CSE: SURE, OTCQB:SURNF) IS ADVANCING SYRACUSE UNIVERSITY’S GEP-44, A NEXT-GENERATION GLP FORMULATION (SIMILAR IN FUNCTION TO OZEMPIC®, WEGOVY®, MOUNJARO®, BUT WITH REDUCED RISK OF ADVERSE EVENTS) TOWARDS FDA APPROVAL AND COMMERCIALIZAT
Slide 3: Disclaimer – Forward Looking Information and Statements
DISCLAIMER – Forward Looking Information and Statements This presentation contains certain forward-looking statements and forward-looking information (collectively referred to herein as “forward-looking statements”) within the meaning of applicable Canadian securities laws. All statements other than
Slide 4: Metabolic Therapeutics Platform – Next-Generation GLP Science
METABOLIC THERAPEUTICS PLATFORM – Next-Generation GLP Science GLUCAPHARM INC., SUBSIDIARY OF SURENANO SCIENCE LTD. (CSE:SURE, OTCQB: SURNF) IS DEVELOPING A NEXT- GENERATION GLUCAGON-LIKE PEPTIDE (“GLP") GEP-44 IN PARTNERSHIP WITH SYRACUSE UNIVERSITY DESIGNED TO ADDRESS OBESITY AND METABOLIC DISEASE
Slide 5: Targeting High Growth Markets
TARGETING HIGH GROWTH MARKETS – Next-Generation GLP Science The GLP-1 drug market is experiencing massive growth, with sales driven by high demand for obesity and diabetes treatments like Ozempic®, Wegovy®, and Zepbound®, which are reshaping the pharmaceutical landscape OBESITY TO HIT $2 BILLION BY
Slide 6: Growing Opportunity
GROWING OPPORTUNITY 6 SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 7: Executive Summary – Microcap Investment Opportunity
EXECUTIVE SUMMARY – Microcap Investment Opportunity Build A Next-Generation GLP ๏ RARE INVESTMENT OPPORTUNITY IN A MICROCAP, NEXT-GENERATION GLP PEPTIDE THERAPEUTICS COMPANY WITH GLP PORTFOLIO SIMILAR TO BIG PHARMA (LINK): A combination that creates a di erentiated, publicly listed metabolic disease
Slide 8: Lead Asset GEP-44 – Triple-Agonist Design
LEAD ASSET GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity GEP-44 IS A MONOMERIC PEPTIDE THAT ACTS AS A TRIPLE AGONIST ON GLP-1 AND PEPTIDE YY (PYY) RECEPTORS Y1 AND Y2, COMBINING THE BENEFITS OF GLP-1 AND NPY SIGNALLING PATHWAYS SCIENTIFIC CORE THERAPEUTIC SUPERIOR EFFICACY & TOLERABILIT
Slide 9: Glucapharm's GEP-44 Value Proposition
LEAD ASSET GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity GLUCAPHARM’S GEP-44 VALUE PROPOSITION ๏ PROPRIETARY GEP-44 SOLUTION: A patent-protected, triple-agonist peptide targeting the GLP-1 receptor, Neuropeptide Y1 receptor and Neuropeptide Y2 receptor ๏ NEXT GENERATION PEPTIDE COMPOUND
Slide 10: Research & Publications
RESEARCH & PUBLICATIONS 10 SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 11: Glucapharm's GEP-44 Value Proposition
LEAD ASSET GEP-44 – Triple-Agonist Design, Single-Molecule Simplicity GLUCAPHARM’S GEP-44 VALUE PROPOSITION ๏ DEVELOPING NON-INJECTABLE DELIVERY (ORAL, NASAL OR SUBLINGUAL): Expanding patient adoption and long-term market penetration ๏ COMPETITIVE POSITIONING: Next-generation GLP solution vs rst-and
Slide 12: Lead Asset GEP-44 – Breakthrough Peptides Meet Scalable Delivery
LEAD ASSET GEP-44 – Breakthrough Peptides Meet Scalable Delivery SCIENCE: GEP-44 is part of a series of chimeric peptides designed to target 2 key receptors ๏ Neuropeptide Y-receptor (Y2-R) to reduce food intake (FI), and GLP1-R to improve glucose regulation ๏ In preclinical studies (male and female
Slide 13: FDA Pathway – Accelerated Development Timeline
FDA PATHWAY – Accelerated Development Timeline to FDA Approval 6 MONTHS 2025 PRECLINICAL STUDIES Q3-2032 DEMONSTRATING EFFICACY Q2-2026 REGULATORY DRUG AND TOLERABILITY 2025 CONDUCT GMP-CERTIFIED APPROVAL Demonstrates equivalent ef cacy to MANUFACTURING OF Obtain approval from Ozempic in achieving w
Slide 14: Market Comparables – Redefining Metabolic Medicine
MARKET COMPARABLES – Rede ning Metabolic Medicine for the Post-Ozempic Era PRECLINICAL EFFICACY IN NEXT-GENERATION GEP-44 HAS THE POTENTIAL TO COMPETE WITH COMPOUNDS DEVELOPED AS OZEMPIC®, MOUNJARO®, WEGOVY® MOUNJARO® - ELI LILLY OZEMPIC® - NOVO NORDISK WEGOVY® - NOVO NORDISK US$220 BILLION MC US$99
Slide 15: Value Creation for Shareholders
STRATEGIC PARTNERSHIP CREATES VALUE – Vertically Integrated Metabolic Therapeutics Company VALUE CREATION FOR SHAREHOLDERS ๏ VERTICALLY INTEGRATED METABOLIC THERAPEUTICS COMPANY: GlucaPharm contributes a high-value, late-preclinical drug portfolio, GEP-44, public market infrastructure and execution
Slide 16: Management – Experienced Scientific and Capital Markets Executives
MANAGEMENT – Led by Experienced Scienti c and Capital Markets Executives Charles MaLette James Bordian Dr. Robert Doyle Dr. Nihar Pandey Dr. Peter Billing Tara Asfour Chief Executive Of cer, Chief Financial Of cer Obesity Expert Inventor and Advisor Chief Scienti c Of cer Corporate Development Presi
Slide 17: Cap Table
CORPORATE – Tightly Held with Signi cant Upside Potential CAP TABLE (*25/02/2026) TICKER: CSE:SURE | OTCQB:SURNF HEADQUARTER: VANCOUVER, BC SHARES OUTSTANDING: 42,008,799 OPTIONS: 1,500,000 WARRANTS: 15,600,000 FULLY DILUTED: 59,108,799 MARKET CAP: ~$9.8M OFFICER & DIRECTOR OWNERSHIP: ~26% 52 WEEK H
Slide 18: Contact
CONTACT Nihar Pandey Tara Asfour General Chief Scienti c Of cer Corporate Development Corporate Matters e: e: [email protected] e: [email protected] SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com fi fi
Slide 19: Appendix
APPENDIX SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 20: Surenano Science Ltd.
20 SURENANO SCIENCE LTD. CSE: SURE | OTCQB: SURNF www.surenano.com
Slide 21: Surenano Science Ltd. Overview
APPENDIX: SURENANO FOUNDATION – Canadian Nanotechnology for Scienti cally Better Drug Delivery SURENANO SCIENCE LTD. OVERVIEW ๏ SURENANO’S FOCUS ON NANOTECHNOLOGY AND ADVANCED MATERIAL SCIENCE APPLICATIONS IN HEALTH AND WELLNESS TRANSFORMS A SINGLE ASSET INTO A PLATFORM OPPORTUNITY WITH THE INTEGRAT
Surenano Science — Investor Presentation (March 2026) on 6ix